Ascend Wellness Holdings (AAWH) Liabilities and Shareholders Equity (2020 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Liabilities and Shareholders Equity of $872.1 million for Q1 2026, down 4.87% year-over-year from $916.7 million in Q1 2025, and down 3.95% quarter-over-quarter from $907.9 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $872.1 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 4.87% year-over-year to $872.1 million; the TTM figure through Mar 2026 stood at $2.7 billion (down 26.3% YoY), while the FY2025 annual figure was $907.9 million, up 0.83% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $872.1 million, down from $907.9 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $929.4 million in Q2 2024, with the low at $407000.0 in Q3 2025.
- The 5-year median for Liabilities and Shareholders Equity is $899.6 million (2023), against an average of $829.9 million.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 48.39% in 2022, then plunged 99.95% in 2025.
- Ascend Wellness Holdings' Liabilities and Shareholders Equity stood at $872.2 million in 2022, then increased by 5.43% to $919.6 million in 2023, then retreated by 2.08% to $900.4 million in 2024, then grew by 0.83% to $907.9 million in 2025, then declined by 3.95% to $872.1 million in 2026.
- Business Quant data shows AAWH's Liabilities and Shareholders Equity at $872.1 million in Q1 2026, $907.9 million in Q4 2025, and $407000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Ascend Wellness Holdings | 97.42 Mn | 30.42 Mn | 45.49 Mn | 888.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 888.32 Mn |
| Mar 31, 2026 | 872.09 Mn |
| Dec 31, 2025 | 907.93 Mn |
| Sep 30, 2025 | 407,000.00 |
| Jun 30, 2025 | 903.87 Mn |
| Mar 31, 2025 | 916.73 Mn |
| Dec 31, 2024 | 900.43 Mn |
| Sep 30, 2024 | 895.87 Mn |
| Jun 30, 2024 | 929.36 Mn |
| Mar 31, 2024 | 921.86 Mn |
| Dec 31, 2023 | 919.55 Mn |
| Sep 30, 2023 | 907.99 Mn |
| Jun 30, 2023 | 899.56 Mn |
| Mar 31, 2023 | 870.09 Mn |
| Dec 31, 2022 | 872.16 Mn |
| Sep 30, 2022 | 847.21 Mn |
| Jun 30, 2022 | 828.79 Mn |
| Mar 31, 2022 | 714.20 Mn |
| Dec 31, 2021 | 723.44 Mn |
| Sep 30, 2021 | 716.88 Mn |